胃食道接合部腺がん治療薬の世界市場レポート 2025年

胃食道接合部腺がん治療薬市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は16.1％で、81億5,000万米ドルに成長します。予測期間中の成長は、精密腫瘍学への注目、集学的治療アプローチの増加、リキッドバイオプシーの使用拡大、低侵襲治療へのシフト、免疫腫瘍学治療の採用増加によってもたらされます。主な動向としては、臨床診療における次世代シーケンサーの統合、標的放射線療法の革新、分子イメージングにおける進歩、治療計画における人工知能の応用、手術手技の改善などが挙げられます。

肥満率の上昇は、胃食道接合部腺がん（GEJA）治療薬市場の成長を促進すると予想されます。体脂肪の過剰蓄積を特徴とする肥満症は、食生活の乱れ、座りがちなライフスタイル、運動不足、加工食品や高カロリー食品の摂取などの要因により増加しています。GEJA治療薬は、炎症、代謝の乱れ、ホルモンバランスの乱れなど、体重増加の原因となる根本的なメカニズムに対処する上で重要な役割を果たしています。例えば、2024年3月、スイスに本部を置く政府間機関である世界保健機関（WHO）は、世界の約8人に1人が肥満に悩んでいると報告しました。この中には、太りすぎに分類される成人が25億人含まれており、そのうち8億9,000万人が肥満と共存しています。成人のうち43％が太りすぎ、16％が肥満に分類されています。さらに、5歳未満の太りすぎの子供の数は3,700万人に達しました。したがって、肥満率の増加がGEJA治療薬市場の拡大に拍車をかけています。

GEJA治療薬市場の主要企業は、治療効果を高め、患者の転帰を改善し、既存治療に対する耐性に対処するための革新的な併用療法の開発に注力しています。併用療法は、薬剤や治療法などの2つ以上の治療薬を用いて、有効性を向上させ、疾患の複数の側面を同時に標的とするものです。例えば、2024年10月、日本の製薬会社であるアステラス製薬は、フルオロピリミジンおよびプラチナ製剤を含む化学療法と併用するゾルベツキシマブ-clzbの米国食品医薬品局（FDA）の承認を取得しました。ゾルベツキシマブ-clzbは、胃がんやGEJがんで高発現するクローディン18.2を特異的に標的とするファースト・イン・クラスのモノクローナル抗体であり、治療精度と治療効果を向上させる。CLDN18.2を発現しているがん細胞に選択的に結合することにより、治療効果を最適化しつつ、健常組織へのダメージを最小限に抑える標的アプローチが可能となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界胃食道接合部腺がん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の胃食道接合部腺がん治療薬市場：成長率分析
• 世界の胃食道接合部腺がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の胃食道接合部腺がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界胃食道接合部腺がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の胃食道接合部腺がん治療薬市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
• トラスツズマブ
• ラムシルマブ
• 世界の胃食道接合部腺がん治療薬市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 内視鏡検査
• X線
• コンピュータ断層撮影（CT）スキャン
• 陽電子放出断層撮影（PET）スキャン
• 世界の胃食道接合部腺がん治療薬市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 食道切除手術
• 食道拡張
• 化学療法
• 標的療法
• 世界の胃食道接合部腺がん治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の胃食道接合部腺がん治療薬市場トラスツズマブの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単剤療法
• 化学療法との併用療法
• 世界の胃食道接合部腺がん治療薬市場ラムシルマブの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単剤療法
• パクリタキセルとの併用療法

第7章 地域別・国別分析

• 世界の胃食道接合部腺がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の胃食道接合部腺がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 胃食道接合部腺がん治療薬市場：競合情勢
• 胃食道接合部腺がん治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd.
• Daiichi Sankyo Company Limited
• Genentech Inc.
• Incyte Corporation
• Ono Pharmaceutical Co. Ltd.
• BeiGene Ltd.
• Zymeworks Inc.
• Zai Lab Limited
• ImmunoGen Inc.
• Elevar Therapeutics Inc.
• Mirati Therapeutics Inc.
• Shanghai Henlius Biotech Inc.
• Taiho Pharmaceutical Co. Ltd.
• LintonPharm Ltd.
• Celltrion Healthcare Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 胃食道接合部腺がん治療薬市場2029：新たな機会を提供する国
• 胃食道接合部腺がん治療薬市場2029：新たな機会を提供するセグメント
• 胃食道接合部腺がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Gastroesophageal junction adenocarcinoma is a malignant tumor that forms at the junction of the esophagus and stomach, often linked to chronic acid reflux, obesity, and other risk factors. Its treatment options include targeted therapies, immunotherapy, chemotherapy, and surgical procedures designed to slow tumor progression, improve survival rates, and enhance patient outcomes.

The primary therapeutics for gastroesophageal junction adenocarcinoma include trastuzumab and ramucirumab. Trastuzumab is a targeted therapy drug used to treat HER2-positive gastroesophageal junction adenocarcinoma by blocking the HER2 protein, which contributes to cancer growth. Diagnosis is conducted through procedures such as endoscopy, X-ray, computed tomography (CT) scan, and positron emission tomography (PET) scan. Treatment approaches include esophagectomy surgery, esophageal dilation, chemotherapy, and targeted therapy. These therapeutics are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The gastroesophageal junction adenocarcinoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides gastroesophageal junction adenocarcinoma therapeutics market statistics, including the gastroesophageal junction adenocarcinoma therapeutics industry global market size, regional shares, competitors with the gastroesophageal junction adenocarcinoma therapeutics market share, detailed gastroesophageal junction adenocarcinoma therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the gastroesophageal junction adenocarcinoma therapeutics industry. This gastroesophageal junction adenocarcinoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gastroesophageal junction adenocarcinoma therapeutics market size has grown rapidly in recent years. It will grow from $3.85 billion in 2024 to $4.48 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth during the historic period was driven by the rising prevalence of *Helicobacter pylori* infection, the increasing number of Barrett's esophagus cases, the expansion of screening programs, greater investment in research and development, and improved healthcare access.

The gastroesophageal junction adenocarcinoma therapeutics market size is expected to see rapid growth in the next few years. It will grow to $8.15 billion in 2029 at a compound annual growth rate (CAGR) of 16.1%. The projected growth during the forecast period is driven by a focus on precision oncology, an increase in multidisciplinary treatment approaches, the expanding use of liquid biopsies, a shift toward minimally invasive procedures, and the rising adoption of immuno-oncology treatments. Key trends include the integration of next-generation sequencing in clinical practice, innovations in targeted radiation therapy, advancements in molecular imaging, the application of artificial intelligence in treatment planning, and improvements in surgical techniques.

The rising obesity rates are expected to drive the growth of the gastroesophageal junction adenocarcinoma (GEJA) therapeutics market. Obesity, a condition characterized by excessive body fat accumulation, is increasing due to factors such as poor dietary habits, sedentary lifestyles, lack of physical activity, and the consumption of processed and high-calorie foods. GEJA therapeutics play a crucial role in addressing the underlying mechanisms that contribute to weight gain, including inflammation, metabolic disruption, and hormonal imbalances, which can be exacerbated by the disease. For instance, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people worldwide were struggling with obesity. This included 2.5 billion adults classified as overweight, with 890 million of them living with obesity. Among adults, 43% were overweight, and 16% were classified as obese. Additionally, the number of overweight children under the age of 5 reached 37 million. Therefore, the growing obesity rates are fueling the expansion of the GEJA therapeutics market.

Leading companies in the GEJA therapeutics market are focused on developing innovative combination therapies to enhance treatment efficacy, improve patient outcomes, and address resistance to existing treatments. Combination therapy involves using two or more therapeutic agents, such as drugs or treatment modalities, to improve effectiveness and target multiple aspects of a disease simultaneously. For example, in October 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for zolbetuximab-clzb in combination with fluoropyrimidine- and platinum-containing chemotherapy. Zolbetuximab-clzb is a first-in-class monoclonal antibody specifically targeting Claudin 18.2, a protein highly expressed in gastric and GEJ cancers, thereby improving treatment precision and effectiveness. By selectively binding to CLDN18.2-expressing cancer cells, this therapy enables a targeted approach, minimizing damage to healthy tissues while optimizing therapeutic outcomes.

In January 2023, Leap Therapeutics Inc., a US-based biotech company, acquired Flame Biosciences Inc. for $115 million. This acquisition strengthens Leap Therapeutics' oncology pipeline by integrating innovative cancer therapies developed by Flame Biosciences, expanding its portfolio of targeted treatments, and advancing research efforts to develop cutting-edge solutions for GEJA and other cancers. Flame Biosciences Inc., a US-based company, specializes in developing therapeutics for gastroesophageal junction adenocarcinoma, further enhancing Leap Therapeutics' capabilities in this market.

Major players in the gastroesophageal junction adenocarcinoma therapeutics market are Pfizer Inc., F Hoffmann-La Roche AG, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Genentech Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., Zymeworks Inc., Zai Lab Limited, ImmunoGen Inc., Elevar Therapeutics Inc., Mirati Therapeutics Inc., Shanghai Henlius Biotech Inc., Taiho Pharmaceutical Co. Ltd., LintonPharm Ltd., Celltrion Healthcare Co. Ltd.

North America was the largest region in the gastroesophageal junction adenocarcinoma therapeutics market in 2024. The regions covered in gastroesophageal junction adenocarcinoma therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastroesophageal junction adenocarcinoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastroesophageal junction adenocarcinoma therapeutics market includes revenues earned by entities by providing services such as radiation therapy, immunotherapy, surgical oncology, and palliative care and related products such as angiogenesis inhibitors, chemoradiation therapy, biosimilars, and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastroesophageal Junction Adenocarcinoma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastroesophageal junction adenocarcinoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastroesophageal junction adenocarcinoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastroesophageal junction adenocarcinoma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug: Trastuzumab; Ramucirumab
• 2) By Diagnosis: Endoscopy; X-ray; Computed Tomography (CT) Scan; Positron Emission Tomography (PET) Scan
• 3) By Treatment: Esophagectomy Surgery; Esophageal Dilation; Chemotherapy; Targeted Therapy
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Trastuzumab: Monotherapy; Combination Therapy With Chemotherapy
• 2) By Ramucirumab: Monotherapy; Combination Therapy With Paclitaxel
• Companies Mentioned: Pfizer Inc.; F Hoffmann-La Roche AG; Merck & Co. Inc.; Bristol-Myers Squibb Company; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Characteristics

3. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Trends And Strategies

4. Gastroesophageal Junction Adenocarcinoma Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gastroesophageal Junction Adenocarcinoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth Rate Analysis
• 5.4. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Total Addressable Market (TAM)

6. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Segmentation

• 6.1. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trastuzumab
• Ramucirumab
• 6.2. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endoscopy
• X-ray
• Computed Tomography (CT) Scan
• Positron Emission Tomography (PET) Scan
• 6.3. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Esophagectomy Surgery
• Esophageal Dilation
• Chemotherapy
• Targeted Therapy
• 6.4. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.5. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Sub-Segmentation Of Trastuzumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy With Chemotherapy
• 6.6. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Sub-Segmentation Of Ramucirumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy With Paclitaxel

7. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Regional And Country Analysis

• 7.1. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 8.1. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 9.1. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
• 9.2. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 10.1. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 11.1. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
• 11.2. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 12.1. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 13.1. Indonesia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 14.1. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
• 14.2. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 15.1. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
• 15.2. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 16.1. UK Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 17.1. Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 18.1. France Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 19.1. Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 20.1. Spain Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 21.1. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
• 21.2. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 22.1. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 23.1. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
• 23.2. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 24.1. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
• 24.2. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 25.1. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
• 25.2. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 26.1. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
• 26.2. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 27.1. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 28.1. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
• 28.2. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market

• 29.1. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
• 29.2. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Competitive Landscape
• 30.2. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Daiichi Sankyo Company Limited
• 31.3. Genentech Inc.
• 31.4. Incyte Corporation
• 31.5. Ono Pharmaceutical Co. Ltd.
• 31.6. BeiGene Ltd.
• 31.7. Zymeworks Inc.
• 31.8. Zai Lab Limited
• 31.9. ImmunoGen Inc.
• 31.10. Elevar Therapeutics Inc.
• 31.11. Mirati Therapeutics Inc.
• 31.12. Shanghai Henlius Biotech Inc.
• 31.13. Taiho Pharmaceutical Co. Ltd.
• 31.14. LintonPharm Ltd.
• 31.15. Celltrion Healthcare Co. Ltd.

32. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastroesophageal Junction Adenocarcinoma Therapeutics Market

34. Recent Developments In The Gastroesophageal Junction Adenocarcinoma Therapeutics Market

35. Gastroesophageal Junction Adenocarcinoma Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer